347 related articles for article (PubMed ID: 28812378)
1. Bevacizumab in advanced lung cancer: state of the art.
Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
[TBL] [Abstract][Full Text] [Related]
2. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in Cervical Cancer: 5 Years After.
Pfaendler KS; Liu MC; Tewari KS
Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
[TBL] [Abstract][Full Text] [Related]
5. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
Kim MM; Umemura Y; Leung D
Cancer J; 2018; 24(4):180-186. PubMed ID: 30119081
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
9. [Bevacizumab in the first-line therapy of advanced NSCLC].
Hasenöhrl N
Wien Med Wochenschr; 2007; 157(21-22):576-8. PubMed ID: 18157597
[TBL] [Abstract][Full Text] [Related]
10. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
12. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
13. Role of bevacizumab for the treatment of non-small-cell lung cancer.
Ramalingam S; Belani CP
Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
Greillier L; Tomasini P; Barlesi F
Ther Adv Respir Dis; 2016 Oct; 10(5):485-91. PubMed ID: 27340254
[TBL] [Abstract][Full Text] [Related]
15. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.
Roviello G; Francini E; Perrella A; Laera L; Mazzei MA; Guerrini S; Petrioli R
Cancer Biol Ther; 2015; 16(12):1720-5. PubMed ID: 26418066
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Garcia J; Hurwitz HI; Sandler AB; Miles D; Coleman RL; Deurloo R; Chinot OL
Cancer Treat Rev; 2020 Jun; 86():102017. PubMed ID: 32335505
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study.
Ai B; Zhang L; Huang D; Chen J; Liu Z; Hu X; Zhou S; Hu Y; Zhao J; Yang F
Thorac Cancer; 2020 Dec; 11(12):3641-3644. PubMed ID: 33073527
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer.
Liu KJ; Ding LY; Wu HY
Tumour Biol; 2015 Mar; 36(3):1323-7. PubMed ID: 25731729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
